VIVIMEDLAB — Vivimed Labs Balance Sheet
0.000.00%
HealthcareAdventurousMicro Cap
Annual balance sheet for Vivimed Labs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 505 | 64.3 | 71.8 | 37.6 | 722 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,902 | 2,482 | 1,868 | 1,729 | 1,968 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 9,753 | 5,287 | 5,073 | 3,323 | 3,426 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 7,875 | 4,083 | 4,026 | 2,988 | 2,835 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 22,096 | 12,893 | 12,660 | 9,883 | 9,509 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7,704 | 3,411 | 3,734 | 4,243 | 4,103 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 13,750 | 8,578 | 9,017 | 9,489 | 9,564 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 8,346 | 4,316 | 3,643 | 394 | -54.6 |
Total Liabilities & Shareholders' Equity | 22,096 | 12,893 | 12,660 | 9,883 | 9,509 |
Total Common Shares Outstanding |